Research location
Tianjing
China
Advertisement
Research activity in Tianjing
ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 10 trials and 12 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tianjing
10 linked trials · page 1 of 1Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaNCT07161388 · 2025-11-17 · 2 site observations
RECRUITING
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNCT07135141 · 2025-09-30 · 1 site observation
NOT_YET_RECRUITING
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCNCT07376629 · 2025-08-14 · 1 site observation
ENROLLING_BY_INVITATION
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)NCT04998032 · 2021-10-12 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)NCT04740918 · 2021-06-07 · 1 site observation
TERMINATED
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT04630808 · 2020-11-09 · 2 site observations
COMPLETED
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerNCT04205812 · 2020-09-11 · 1 site observation
COMPLETED
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerNCT03520478 · 2018-05-30 · 1 site observation
UNKNOWN
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385 · 2017-03-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.